Alliancebernstein L.P. Astria Therapeutics, Inc. Transaction History
Alliancebernstein L.P.
- $278 Billion
- Q2 2024
A detailed history of Alliancebernstein L.P. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 54,020 shares of ATXS stock, worth $601,782. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,020
Previous 49,370
9.42%
Holding current value
$601,782
Previous $694,000
29.25%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding ATXS
# of Institutions
102Shares Held
49.4MCall Options Held
27.6KPut Options Held
29.7K-
Perceptive Advisors LLC New York, NY6.49MShares$72.2 Million1.71% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.04MShares$56.2 Million0.69% of portfolio
-
Vr Adviser, LLC New York, NY3.61MShares$40.2 Million3.6% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$39.6 Million6.42% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$39.2 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $169M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...